A Phase 2 interventional study of Monoferric Injectable Product and 0.9% sodium chloride solution in Chronic Iron Deficiency Anaemia and Cardiac Surgery, sponsored by University Health Network, Toronto. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing iron isomaltoside 1000 in Iron Deficiencies — 9 open to participants now, 9 under way, 2 of them phase 3. iron isomaltoside 1000 · Iron Deficiencies.
Among the 21 studies testing iron isomaltoside 1000 in Iron Deficiencies, this one is the 19th largest by planned enrollment, is one of 4 that started in 2025, is the only one in phase 2, and was the 16th registered.
386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.
Browse Iron Deficiencies studies →9 of the 21 studies testing iron isomaltoside 1000 in Iron Deficiencies are open now, in 4 countries. Recruiting first, the newest first:
Pharmacosmos A/S · Sites in United States
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18–65
China-Japan Friendship Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18+
China-Japan Friendship Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 10 · Phase 4 7
First in 2009; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 60 is below the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 170 across the 21 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 21 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
University Health Network, Toronto has 1 study filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
6 of the studies testing iron isomaltoside 1000 in Iron Deficiencies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179226Phase 3Pharmacosmos A/SMulti-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia | 2027-04-30 |
| NCT06287619University Health Network, TorontoPost-operative Intravenous Iron to Treat Iron-deficiency Anemia in Patients Undergoing Cardiac Surgery | 2026-12 |
| NCT07236788China-Japan Friendship HospitalStudy on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency. | 2026-12-30 |
| NCT05971732China-Japan Friendship HospitalThe Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF) | 2027-08-01 |
| NCT05991128China-Japan Friendship HospitalThe Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life | 2027-08-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 21 studies testing iron isomaltoside 1000 in Iron Deficiencies, from their registry updates:
This tab as a report to print or save as PDF → With an account.
POAM is a multicenter, randomized, controlled, internal pilot trial, using a conventional, parallel group, two-armed design at 3 cardiac surgery centres in Canada. The study is designed to assess the feasibility of a future, definitive RCT investigating whether, in patients with chronic iron-deficiency anemia undergoing cardiac surgery, IV iron therapy in the postoperative period (initiated shortly after surgery, and repeated at 42 days after surgery, if needed) improves clinical outcomes (days alive and out of hospital at 90 days after surgery; DAOH-90) relative to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who are undergoing any non-emergency open cardiac surgery and who meet all following criteria:
Preoperative iron-deficiency with or without anemia (defined as \<130 g/L) with any one of:
Exclusion Criteria:
Patients who meet any of the following criteria are not eligible for the study:
established to IV iron:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the IV iron group will receive 1000 mg ferric derisomaltose (Monoferric) diluted in 100 mL of 0.9 % sodium chloride solution, via intravenous infusion over 1 hour using an opaque IV bag and tubing for blinding.
Drug: Monoferric Injectable Product
Patients randomized to the placebo group will receive 100 mL of 0.9 % sodium chloride solution via intravenous infusion using an opaque IV bag and tubing for blinding.
Other: 0.9% sodium chloride solution
Ferric derisomaltose will be prepared by an unblinded research pharmacist/delegated staff as per standard of care procedures. Specifically, 10 mL (containing 1000 mg ferric derisomaltose) will be diluted in 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing. The 1000 mg doses of ferric derisomaltose will be administered by a bedside nurse over 60 minutes via an infusion pump through a dedicated IV.
Also known as: Ferric derisomaltose
Patients in the control group will receive placebo, which will be 100 mL of sterile 0.9% sodium chloride solution and drawn up into blinded syringes and tubing according to good manufacturing practice (GMP).
Feasibility Outcome 1: Percentage of major protocol deviations
Percentage of major protocol deviations with a feasibility threshold of ≤ 5% (i.e., treatment not according to randomization allocation or dosing schedule; treatment initiated in ineligible patients or outside of allotted periods)
Time frame: through study completion, an average of 1 year.
Feasibility Outcome 2: Adequate patient enrollment
Adequate patient enrollment defined as ≥20% of eligible patients enrolled.
Time frame: through study completion, an average of 1 year.
Feasibility Outcome 3: Percentage of patients lost to follow-up at 90 days
Percentage of patients lost to follow-up at 90 days with a feasibility threshold of ≤ 5%.
Time frame: through study completion, an average of 1 year.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron isomaltoside 1000
University Health Network, Toronto →